Source-grounded facts extracted from Lipocine Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lipocine Inc. reported First Quarter Ended March 31, 2026 results: net income net loss of $3.7 million, EPS ($0.52) per diluted share.
“Lipocine reported a net loss of $3.7 million, or ($0.52) per diluted share, for the quarter ended March 31, 2026, compared with a net loss of $1.9 million, or ($0.35) per diluted share, for the quarter ended March 31, 2025.”
Lipocine Inc.: Reduction of authorized common stock from 200,000,000 to 75,000,000 shares via amendment to Amended and Restated Certificate of Incorporation (effective 2025-06-04).
“On June 4, 2025, the Company filed the Amendment with the Secretary of State of the State of Delaware.”
Lipocine Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at terminated effective immediately upon notice; waiver of notice period (effective 2024-04-24).
“On April 24, 2024, the Company provided notice to Cantor Fitzgerald & Co. (“Cantor”) of its election to terminate the Controlled Equity Offering SM Sales Agreement between them dated March 6, 2017 (the “Sales Agreement”).”
Lipocine Inc. entered into ATM Agreement with A.G.P./Alliance Global Partners valued at up to $10,616,169 of Shares; 3.0% of aggregate gross proceeds per sale (effective 2024-04-26).
“On April 26, 2024, Lipocine Inc. (the “Company”), entered into a sales agreement (the “ATM Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.0001 per share (the “Shares”), from time to time, in an at-the-market public offering.”
Lipocine Inc. reported the year ended December 31, 2023 results: revenue $2.9 million, net income net loss of $16.4 million, EPS ($3.14) per diluted share.
“per diluted share, for the year ended December 31, 2022. During 2023 Lipocine recognized a non-cash minimum guaranteed royalties reversal of variable consideration revenue of $2.9 million related to the termination of the Antares License Agreement. The reversal of revenue is due to the fact that, as a result of the termination of the license agreement, the Company”
Lipocine Inc. entered into License Agreement with Gordon Silver Limited and Verity Pharmaceuticals, Inc. valued at $11 million license fee (effective 2024-01-12).
“On January 12, 2024, Lipocine Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Gordon Silver Limited (“GSL”) and Verity Pharmaceuticals, Inc. (“Verity Pharma”)”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.